Biofrontera Inc., a key player in the dermatology sector, has announced a significant expansion in its operations by acquiring all U.S. assets related to Ameluz® and RhodoLED® from Germany-based Biofrontera AG. This strategic move, backed by an $11 million investment, aims to strengthen the company's presence in the U.S. market. As part of the agreement, Biofrontera Inc. will take over full responsibility for the manufacturing, regulatory, and commercial operations associated with these products in the U.S. The effective royalty rate paid by Biofrontera Inc. will be reduced significantly, allowing the company to reach profitability more swiftly. The transaction also aligns the long-term interests of both entities, with Biofrontera AG receiving a 10% equity stake in Biofrontera Inc. This expansion reflects Biofrontera Inc.'s commitment to enhancing its capabilities and unlocking the potential of its dermatology treatments.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.